Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of harpagoside in pharmacy

A technology of harpagoside and drug, applied in the pharmaceutical field of harpagoside, can solve the problem that the effect of PD cell model and PD overall animal model has not been reported yet.

Inactive Publication Date: 2011-09-28
SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its effect on PD cell model and PD whole animal model has not been reported yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of harpagoside in pharmacy
  • Application of harpagoside in pharmacy
  • Application of harpagoside in pharmacy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0083] Example 1: Protection of harpagoside against MPTP + induced neuronal damage

[0084] Method: The culture of dopamine neurons in the midbrain was the same as before, and the treatment was as follows figure 1 A's experimental protocol.

[0085] Determination of cell viability: MTT method was used. Wash the cultured cells once with PBS, add MTT (0.5mg / ml) to each well, incubate for 4 hours, discard the supernatant, add DMSO, shake on the shaker for 15 minutes to completely dissolve, and read the absorbance at 490nm with a microplate reader. Cell viability = (without MPTP + Group OD-plus MPTP + group OD) / (without MPTP + group OD-MPTP + Group OD) × 100%, to obtain the change value of the number of viable cells.

[0086] Results: MPTP was observed in the experiment of cell viability assay + Toxic effect on primary nerve cell damage, adding different concentrations of harpagoside (10 -6 M, 10 -5 M) The percentage of surviving cells increased from 65.0% to 80.9% and 8...

Embodiment 2

[0091] Embodiment 2: Harpagoside to MPP + Protective effect of injured midbrain dopamine neurons

[0092] Immunocytochemical staining of midbrain dopamine neuron tyrosine hydroxylase (tyrosine hydroxylase, TH), the change of TH positive (+) cell number is the hallmark enzyme of PD. figure 2 A is to adopt figure 1A picture of the experimental protocol obtained. Observe under a Nikon inverted microscope, take 10 pictures for each culture well under a 100-fold magnification field of view, count the number of TH-positive neurons, and measure the longest process of each TH-positive neuron in the field of view under a 200-fold magnification , used to assess the neurite length of TH-positive neurons.

[0093] figure 2 B shows an increase in the number of midbrain TH(+) neurons as the concentration of harpagoside increased from 0.1 μM to 10 μM. 1 μM and 10 μM harpagoside make MPP + The relative number of injured midbrain TH(+) neurons increased from (0.604±0.010) to (0.739±0.0...

Embodiment 3

[0096] Embodiment 3: Harpagoside to MPP + Repair of damaged midbrain dopamine neurons (therapy)

[0097] image 3 A is to adopt figure 1 Experimental scheme of B, immunocytochemical staining to obtain pictures of dopamine neurons in the midbrain. Counting the number and neurite length of TH-positive neurons showed that 10 μM harpagoside in MPP + Added to the cell culture system 24 hours after injury, as the concentration of harpagoside increased from 0.1 μM to 100 μM, the number of midbrain TH(+) neurons ( image 3 B) and protrusion length ( image 3 C) shows an increasing trend. 10 μM and 100 μM harpagoside made MPP + The relative number of injured midbrain TH(+) neurons increased from (0.699±0.020) to (0.781±0.021) and (0.824±0.018), respectively increased by 11.7% (P+ The number and neurite length of injured midbrain TH(+) neurons were not significantly affected (both P>0.05).

[0098] The above results prove that the MPP + The damage was then treated with harpagosi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention develops new applications of harpagoside in medical treatment and health care, and exploits a new application area. The invention approves that oral administration of harpagoside has an obvious protective action on degenerative change of nigrostriatal dopaminergic neurons of the central nervous system, and such protective action comprises two aspects of prevention and treatment; theinvention also approves that the harpagoside is closely related to the improvement of the gene expression and protein levels of glial cell line-derived neurotrophic factor (GDNF), thereby solving theproblem that although the GDNF has actions on preventing and treating the degenerative change of the nigrostriatal dopaminergic neurons, the GDNF can not pass through the blood brain barrier; and theinvention approves that the harpagoside has good application prospects in treating or preventing neurodegenerative diseases, especially Parkinson's disease.

Description

【Technical field】 [0001] The present invention relates to the application of harpagoside in pharmacy. 【Background technique】 [0002] Common diseases of the central nervous system such as Parkinson's disease (Parkinson'Disease, PD) are getting more and more attention. Although its primary cause has not yet been elucidated, it has become more and more clear that it is a neurodegenerative disease with the deepening of research. Parkinson's disease is mainly caused by the degeneration of nerve cells related to the motor system, and these changes are closely related to the degeneration of dopamine neurons in the substantia nigra caused by oxygen stress. At present, the clinical treatment of this disease is mainly symptomatic therapy, mainly using dopa drugs, which cannot improve the progress of neurodegeneration, and long-term use may even lead to aggravation of the disease. [0003] At present, drugs that can delay or correct neurodegeneration are being vigorously studied int...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A23L1/29A61P25/16A23L33/00
Inventor 胡雅儿夏宗勤张永芳熊中奎
Owner SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE